



Exelixis Announces January 13 Webcast of Presentation at the 27th Annual JPMorgan Healthcare Conference

December 18, 2008

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 18, 2008--Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis will present at the 27th Annual JPMorgan Healthcare Conference at 8:00 a.m. PT / 11:00 a.m. ET on Tuesday, January 13, 2009. Dr. Scangos will discuss the company's corporate strategy and development pipeline.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase III, Phase II and Phase I clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's website at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.

CONTACT: Exelixis, Inc.

Investor Contact:

Charles Butler, 650-837-7277

Senior Director, Corporate Communications

cbutler@exelixis.com

Media Contact:

Soleil Maxwell Harrison, 650-837-7012

Senior Manager, Corporate Communications

sharriso@exelixis.com

Source: Exelixis, Inc.